Acute Myeloid Leukemia Pipeline Assessment 2022 report covers Unmet Needs, Key Opportunities, and Major Players by DelveInsight

DelveInsight highlights recent progress and expected entry of Acute Myeloid Leukemia emerging therapies, including all phases of drug developments

DelveInsight's "Acute Myeloid Leukemia Pipeline Insight'' report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Acute Myeloid Leukemia pipeline landscape. It comprises Acute Myeloid Leukemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Myeloid Leukemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Myeloid Leukemia pipeline products.

To know more about Acute Myeloid Leukemia Clinical Trials, click here: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the significant Acute Myeloid Leukemia Pipeline Report Highlights
• Key players that are developing the drugs for the treatment of Soft Tissue Sarcoma include- Rafael Pharmaceuticals, Moleculin Biotech, BioSight, Abbvie, Jazz Pharmaceuticals, Amgen, AstraZeneca, Menarini Group, Polaris Group, Innovent Biologics, Helsinn Healthcare, Actinium Pharmaceuticals, Arog Pharmaceuticals, BerGenBio, and many others.
• In December 2020, Rafael Pharmaceuticals announced that the USFDA has granted Fast Track designation for the Company's lead compound, CPI-613 (devimistat), for the treatment of acute myeloid leukemia (AML). The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613® as an orphan drug for the treatment of pancreatic cancer, AML, Myelodysplastic syndromes (MDS), peripheral T-cell lymphoma and Burkitt's lymphoma. The EMA has granted orphan drug designation to CPI-613® for pancreatic cancer and AML.
• Results from an ongoing Phase 2b study, demonstrate that aspacytarabine treatment of AML patients is safe and well-tolerated, enabling delivery of high doses of cytarabine to older and unfit patients, leading to durable responses and prolonged survival. In December 2020, Biosight announced the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to aspacytarabine (BST-236) for the treatment of acute myeloid leukemia (AML). Aspacytarabine was granted FDA Fast Track Designation for first-line treatment of AML patients unfit for standard chemotherapy, and Orphan Drug Designation.
• In July 2020, Amgen initiated Phase-I clinical trials of AMG 330 in Acute myeloid leukemia (Combination therapy, Second-line therapy, or greater) in the USA (IV) (NCT04478695)

To know more about Acute Myeloid Leukemia Pipeline Overview, Click here: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute Myeloid Leukemia or Acute Myelogenous Leukemia (AML) is a type of blood cancer. Acute Myeloid Leukemia causes include a DNA mutation in the stem cells in the bone marrow. The mutation causes the stem cells to produce many more white blood cells than needed. It is the most common in older people.
Acute Myeloid Leukemia treatment comprises chemotherapy, sometimes along with a targeted therapy drug. A stem cell transplant might follow this. Other drugs (besides standard chemotherapy drugs) may treat people with acute promyelocytic leukemia (APL). The most common remission induction regimens for AML include a drug called cytarabine, most often given continuously for seven days through an intravenous (IV) line.

Acute Myeloid Leukemia Pipeline Therapeutics

• CPI-613 (Devimistat) : Rafael Pharmaceuticals
Rafael's first-in-class clinical lead compound, CPI-613® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613® is being evaluated in multiple Phase I, I/II, II, and III clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. The drug is in phase 3 of clinical trials for Acute Myeloid Leukemia and has received Fast Track designation for Acute myeloid leukemia [IV, Infusion] (Combination therapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in the USA.

• Bemcentinib: BerGenBio
Bemcentinib (BGB324) is a potent, selective, and orally bioavailable AXL inhibitor and the most-advanced selective AXL inhibitor in clinical trials. The BGBC003 trial is a Phase Ib/II multi-center open-label study of bemcentinib in combination with cytarabine (part B2) and decitabine (part B3) in patients with AML who are unsuitable for intensive chemotherapy as a result of advanced age or existing-comorbidities.

• Aspacytarabine : BioSight
Aspacytarabine (BST-236 ) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Results from an ongoing Phase 2b study, demonstrate that aspacytarabine treatment of AML patients is safe and well-tolerated, enabling delivery of high doses of cytarabine to older and unfit patients, leading to durable responses and prolonged survival.

• Annamycin liposomal : Moleculin Biotech
Annamycin is an anthracycline being developed for the treatment of relapsed or refractory acute myeloid leukemia or AML. Annamycin is a unique next-generation liposome formulated anthracycline (also referred to in the literature as "L-Annamycin") that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines. The drug is currently in phase I/II of clinical trials for the treatment of relapsed or refractory Acute Myeloid Leukemia.

For further product profiles, request Acute Myeloid Leukemia Pipeline Sample Report: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Acute Myeloid Leukemia Pipeline Drug Insight
• Coverage: Global

• Major Players: 100+ Key Players

• Prominent Players: Rafael Pharmaceuticals, Moleculin Biotech, BioSight, Abbvie, Jazz Pharmaceuticals, Amgen, AstraZeneca, Astex Pharmaceuticals, Menarini Group, Polaris Group, Innovent Biologics, Helsinn Healthcare, Actinium Pharmaceuticals, Arog Pharmaceuticals, BerGenBio, and many others.

• Key Drugs Profiles: 100+ Products

• Phases:
1. Acute Myeloid Leukemia Therapies Late-stage (Phase III)
2. Acute Myeloid Leukemia Therapies (Phase II)
3. Acute Myeloid Leukemia Therapies (Phase I)
4. Acute Myeloid Leukemia Therapies Pre-clinical stage and Discovery candidates
5. Discontinued and Inactive candidates

• Molecule Types:
1. Small molecule
2. Gene therapy
3. Stem cell therapy

• Mechanism of Action:
1. Protease inhibitors
2. Immunomodulatory
3. Multiple kinase inhibitor

• Route of Administration:
1. Oral
2. Inhalation
3. Subcutaneous
4. Intravenous

• Product Types:
1. Monotherapy
2. Combination

To get free access to Sample Report: https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Questions regarding Current Acute Myeloid Leukemia Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
• What are the current options for Acute Myeloid Leukemia treatment?
• How many companies are developing therapies for the treatment of Acute Myeloid Leukemia?
• How many Acute Myeloid Leukemia emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Acute Myeloid Leukemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Acute Myeloid Leukemia market?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Acute Myeloid Leukemia?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Acute Myeloid Leukemia therapies?
• What are the key designations that have been granted for the emerging therapies for Acute Myeloid Leukemia?
• How many patents are granted and pending for the emerging therapies for the treatment of Acute Myeloid Leukemia?

To get free access to Sample Report: https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Acute Myeloid Leukemia Introduction
2. Acute Myeloid Leukemia Executive Summary
3. Acute Myeloid Leukemia Overview
4. Acute Myeloid Leukemia Analytical Perspective In-depth Commercial Assessment
5. Acute Myeloid Leukemia Pipeline Therapeutics
5.1. Acute Myeloid Leukemia Late Stage Products (Phase III)
5.1.1. CPI-613: Rafael Pharmaceuticals
5.1.2. Uproleselan: GlycoMimetics Incorporated
5.2. Acute Myeloid Leukemia Mid Stage Products (Phase II)
5.2.1. BST 236: BioSight Ltd.
5.3. Acute Myeloid Leukemia Early Stage Products (Phase I/II)
5.3.1. Annamycin liposomal: Moleculin Biotech
5.4. Early Stage Products (Phase I)
5.4.1. ABBV-744: Abbvie
6. Acute Myeloid Leukemia Therapeutic Assessment
7. Acute Myeloid Leukemia Inactive Products
8. Company-University Collaborations (Licensing/Partnering) Acute Myeloid Leukemia Analysis
9. Acute Myeloid Leukemia Key Companies
10. Acute Myeloid Leukemia Key Products
11 . Acute Myeloid Leukemia Unmet Needs
12. Acute Myeloid Leukemia Market Drivers and Barriers
13. Acute Myeloid Leukemia Future Perspectives and Conclusion
14. Acute Myeloid Leukemia Analyst Views
15. Appendix
16. About DelveInsight

Download TOC for Acute Myeloid Leukemia Report: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Latest Report:
Familial Primary Pulmonary Hypertension Market
https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bone Grafts And Substitutes Market
https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

22q11.2 Deletion Syndrome Market
https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Human Papilomavirus Market
https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hip Replacement Devices Market
https://www.delveinsight.com/report-store/hip-reconstruction-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ashermans Syndrome Market
https://www.delveinsight.com/report-store/ashermans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.